A unique feature of p21 that distinguishes it from the other cyclin-dependent kinase (CDK) inhibitors is its ability to associate with the proliferating cell nuclear antigen (PCNA), an auxiliary factor for DNA polymerases d and e. While it is now well established that inhibition of cyclin/CDK complexes by p21 can result in G1 cell cycle arrest, the consequences of p21/PCNA interaction on cell cycle progression have not yet been determined. Here, we show, using a tetracyclineregulated system, that expression of wild-type p21 in p53-de®cient DLD1 human colon cancer cells inhibits DNA synthesis and causes G1 and G2 cell cycle arrest. Similar eects are observed in cells expressing p21 CDK7 , a mutant impaired in the interaction with CDKs, but not in cells expressing p21 PCNA7 , a mutant de®cient for the interaction with PCNA. Analysis of cells treated with a p21-derived PCNA-binding peptide provides additional evidence that the growth inhibitory eects of p21 and p21 CDK7 result from their ability to bind to PCNA. Our results suggest that p21 might inhibit cell cycle progression by two independent mechanisms, inhibition of cyclin/CDK complexes, and inhibition of PCNA function resulting in both G1 and G2 arrest.
Introduction
Over the last few years a new class of cell cycle regulators, the cyclin-dependent kinase inhibitors (CKIs), has been the focus of a great deal of attention. The major interest for these proteins stems mainly in the connections their discovery allowed to establish between the growth control pathways and the cell cycle machinery (Elledge et al., 1996) . Although all the inhibitors function to block the activity of cyclindependent kinases (CDKs) ± the key protein kinases that regulate major cell cycle transitions ± they belong to two dierent classes that have been de®ned on the basis of their primary sequences and their biochemical properties. Members of the CIP/KIP family (p21Cip1, p27Kip1 and p57Kip2) inhibit the activity of the CDKs through their binding to the enzymatic complexes formed by the association of CDK catalytic subunits with cyclin regulatory subunits. A conserved bipartite motif located in the amino-terminal part of these inhibitors is required for binding and inhibition of cyclin-CDK complexes both in vitro and in vivo (Fotedar et al., 1996; Goubin and Ducommun, 1995; Nakanishi et al., 1995; Zakut and Givol, 1995) . The INK4 family members (p16, p15, p18 and p19) function dierently by forming speci®c binary complexes with CDK4 and CDK6 that prevent association of these CDKs with cyclin D and thus result in inhibition of pRb-dependent cell cycle progression in G1 Medema et al., 1995; Serrano et al., 1993) . A number of studies have now clearly established links between CKI expression and developmental events or cancer predisposition (for review see Elledge et al., 1996) . In all these situations, CKIs appear to regulate cell cycle progression through the modulation of cyclin/CDK complexes activity in response to various intracellular or extracellular signals.
p21Cip1/Waf1 (hereafter referred to as p21) is a key mediator of the growth arrest induced by the tumour suppressor protein p53 in response to DNA damage (ElDeiry et al., 1993) . Accordingly, homozygous deletion of the p21 gene in mouse embryonic ®broblasts or human colon cancer cells partially or completely abrogates the DNA-damage-induced G1 arrest mediated by p53 (Brugarolas et al., 1995; Deng et al., 1995; Waldman et al., 1995) . A unique feature of p21 that distinguishes it from the other CKIs is its ability to associate with the proliferating cell nuclear antigen (PCNA) (Xiong et al., 1992; Zhang et al., 1993) , an auxiliary factor for DNA polymerases d and e, that is essential for both DNA replication and DNA repair (Kelman, 1997) . p21 contains a PCNA binding motif located in the carboxyterminal part of the protein between residues 144 ± 151 (Chen et al., 1995a; Goubin and Ducommun, 1995; Nakanishi et al., 1995b; Warbrick et al., 1995) . Crystal structure of human PCNA complexed with a 22 residue PCNA-binding peptide (PBP) containing this motif has revealed that the p21 carboxy-terminal domain interacts with the interdomain connector loop of PCNA and is likely to prevent the interaction of PCNA with other components of polymerase assembly (Gulbis et al., 1996) . Although it is still controversial, this C-terminal domain of p21 might inhibit cell cycle progression independently of the N-terminal CDK inhibitory domain and thus contribute to the antiproliferative activity of p21 (Luo et al., 1995; Nakanishi et al., 1995b) . p21 has been shown to inhibit PCNA-dependent DNA replication and mismatch repair in vitro (FloresRozas et al., 1994; Li et al., 1994; Podust et al., 1995; Umar et al., 1996; Waga et al., 1994) . PCNA is also required for nucleotide excision repair but p21 does not appear to block the function of PCNA in this process (Li et al., 1994 (Li et al., , 1996 Shivji et al., 1994) . Recently, p21Cip1 has been shown to impair loading of Fen1 by PCNA on the replication fork (Chen et al., 1996b; Warbrick et al., 1997) . Since Fen1 is an essential exonuclease involved in the processing of ARN-DNA junctions during Okazaki fragments replication, this impairment might contribute to p21-dependent inhibition of replication. In contrast, Fen1 does not appear to be required for nucleotide excision repair and inhibition of PCNA/Fen1 interaction by p21 is therefore unlikely to aect this later process. p21 induction after DNA damage may thus lead to inhibition of cell cycle progression and inactivation of PCNA-dependent DNA replication, while permitting active nucleotide excision repair. This will ensure that any errors caused by the damage are corrected before being propagated by DNA replication.
To further characterize the molecular mechanisms underlying p21 growth suppressive function, we have generated p53-de®cient human colon cancer cell lines expressing wild-type or mutants p21 under the control of a tetracycline-regulated promoter. To dissociate the eects of p21 due to the interaction with CDKs from the eects due to the interaction with PCNA, we used p21 mutants de®cient for either one or the other interaction. Here we report the characterization of the eects of these mutations on cell proliferation and demonstrate that p21-binding to PCNA is sucient to block cell cycle progression at the G1/S and G2/M transitions.
Results
Conditional expression of wild-type and mutant p21 proteins in p53-de®cient human colon cancer cells A conditional expression system regulated by tetracycline removal from the culture media (Gossen and Bujard, 1992) was used to express wild-type and mutant p21 proteins in human DLD1 colorectal carcinoma cells. DLD1 colon cancer cells were chosen for these studies since they carry two mutated alleles of p53, constitutively express very low levels of endogenous p21 (data not shown) and can thus be considered functionally equivalent to p21 7/7 cells (Sheikh et al., 1997; Waldman et al., 1996) . On the basis of previous studies that have identi®ed p21 residues critical for interaction with CDKs and PCNA in the amino-and carboxy-terminal halves of the protein respectively Nakanishi et al., 1995a, b; Warbrick et al., 1995) , we generated p21 mutants impaired in either one or the other interaction. In a mutant called p21 CDK7 , referring to the loss of interaction with CDKs, residues tryptophane 49, phenylalanine 51 and aspartic acid 52 were replaced by arginine, serine, and alanine respectively ( Figure  1a ). These three residues are conserved in the related CKI p27 KIP1 and have been shown on the basis of crystallographic studies to make critical contacts with CDK2 (Russo et al., 1996) . In the mutant called p21 PCNA7 , residues methionine 147, aspartic acid 149 and phenylalanine 150 were mutated to alanine in order to abolish the interaction with PCNA ( Figure  1a ). Residues methionine 147 and phenylalanine 150 have been shown to bind in an hydrophobic pocket under the connector loop of PCNA (Gulbis et al., 1996) . The wild-type and these two mutant p21 cDNAs were cloned downstream of a tetracycline-responsive promoter in the pUHD10 vector described by Gossen and Bujard (1992) . A triple hemagglutinin (HA) tag was also introduced in frame with the p21 sequence at the carboxy-terminus (Figure 1a ) to allow the detection of the protein products and to determine their intracellular localization. Previous studies have shown that this HA tag does not interfere with the growth inhibitory activity of p21 (Nakanishi et al., 1995) . The three constructs were transfected in a derivative of the DLD1 colon carcinoma cell line that was already engineered to express the tTA transactivator (Chen et al., 1995b) . Clones selected for their hygromycin resistance were then screened for conditional expression of p21 wild-type and mutant proteins by indirect immuno¯uorescence microscopy using monoclonal anti-HA antibodies. Three representative clones were selected and used in the experiments reported below. CDK7 and p21 PCNA7 were grown in the presence (+) or in the absence (7) of tetracycline for the indicated times. Cells (5610 4 per lane) were then lysed and expression of HA-tagged proteins was determined by immunoblotting of whole cell lysates with monoclonal anti-HA antibody 12CA5F p21 binding to PCNA causes G1 and G2 growth arrest C Cayrol et al Expression levels of wild-type and mutant p21 in stably transfected DLD1 cell lines were assayed by immunoblotting. Levels of p21 proteins are virtually null in the presence of tetracycline but are increased upon antibiotic removal from the culture media to reach a maximum after about 48 ± 72 h (Figure 1b) . Quantitative immunoblotting experiments (data not shown) with known amounts of puri®ed GST-tagged p21 protein revealed that p21 levels after tetracycline withdrawal (0.15 pg per cell) are similar to the levels that are observed in normal human ®broblasts after u.v.-irradiation (Li et al., 1996) . Since the intracellular localization of p21 has been reported to be nuclear, we also checked the subcellular localization of wild-type p21, p21 CDK7 and p21 PCNA7 mutant proteins 96 h after tetracycline withdrawal. Indirect immuno¯uorescence staining revealed (Figure 2 ) that the three p21 proteins were similarly mainly localized into the nucleus with a very low level of cytoplasmic staining in some cells. These results indicate that the mutations generated in p21 have no detectable eect on its subcellular localization.
In vivo DNA synthesis inhibitory activity of mutant p21 proteins
The ability of wild-type and mutant p21 proteins to inhibit in vivo DNA synthesis was evaluated by measuring bromodeoxyuridine (BrdU) incorporation 4 days after tetracycline removal. The parental DLD1 cell line and the DLD1-derivatives expressing p21, p21 CDK7 or p21 PCNA7 proteins were incubated for 5 h with BrdU and stained with an anti-BrdU monoclonal antibody. As shown in Table 1 , 62.7% of the DLD1 parental cells incorporated BrdU during this time period. In contrast, only 8.7% of the cells expressing wild-type p21 showed BrdU incoporation during the same period, indicating that p21 expression in DLD1 cells resulted in a profound inhibition of S-phase progression. Surprisingly, p21 CDK7 mutant was also able to inhibit BrdU incorporation and was even more potent than wild-type p21 since the percentage of cells in S-phase felt to 4.2% in cells expressing this mutant. This later result suggests that inhibition of DNA synthesis by p21 in DLD1 colon cancer cells is independent of the binding of p21 to CDKs. One possible explanation for these results may be that inhibition of S-phase progression in p21-expressing cells results from p21 binding to and inhibiting PCNA. In agreement with this hypothesis, mutant p21 PCNA7 , which is de®cient for PCNA binding, failed to inhibit BrdU incorporation (Table 1) . Together, these results suggest that PCNA is the primary target of p21 for growth inhibition in DLD1 colon cancer cells .
To obtain additional evidence that p21 exerts its inhibitory eects via interaction with PCNA, we used a 20-residues PCNA-binding peptide derived from p21 (Knibiehler et al., 1996; Warbrick et al., 1995) . This p21 peptide is a potent and speci®c PCNA inhibitor that can capture PCNA from whole cells extracts and inhibit the function of PCNA in DNA replication and mismatch repair in vitro assays (Umar et al., 1996; Warbrick et al., 1995) . To ensure ecient cellular penetration, the p21 peptide was fused to a 16 aminoacid sequence derived from the Antennapedia homeodomain (known as penetratin), that has been shown to translocate eciently through biological membranes in a rapid and energy-independent fashion (Derossi et al., 1994) . Similar carrier-linked peptides have previously been used to map domains of p16 and p21 sucient for inhibition of S-phase entry . The ability of the penetratin-linked p21 wild-type peptide ( Figure 3a ) to inhibit S-phase progression was assessed by staining cells for BrdU incorporation. As shown in Figure 3b , when the chimaeric p21 peptide was added at a concentration of 25 mM to a culture of proliferating asynchronous DLD1 cells during 4 ± 24 h, the number of cells entering S-phase was reduced respectively to 47 and 55% of control levels. This suggests that the p21 peptide mimics the ability of full-length p21 to act as a growth suppressor by inhibiting PCNA. To demonstrate the speci®city of the eects of the p21 peptide, we used a mutant p21 PCNA7 peptide, in which residues critical for the interaction with PCNA (M147, D149, F150) were all changed to alanine ( Figure 3a) . No signi®cant inhibition of DNA synthesis was observed with this mutant p21 PCNA7 peptide ( Figure 3b ). We checked the binding properties of these two peptides to PCNA using the surface plasmon resonance (SPR)-based assay known as BIAcore (Pharmacia). Figure 3c shows a typical sensorgram obtained using 10 mM of both peptides injected on a sensorchip prepared with puri®ed PCNA. For the wild-type peptide the association (k on ) and dissociation (k (Chen et al., 1996a) . In contrast, when the mutated peptide was used, the interaction with PCNA was totally abolished as indicated by the lack of association phase. The upward and downward shifts of the baseline are independent of the actual binding between the analyte and the ligand and are only due to buer refringence dierences. Together, the in vitro and in vivo data obtained with the two peptides indicate that there is a strict correlation between the capacity of the peptide to bind PCNA and to inhibit DNA synthesis. Furthermore, these data strongly suggest that p21 binding to PCNA is responsible for the inhibition of DNA synthesis by p21 in DLD1 colon cancer cells.
p21 and p21
CDK7 mutant arrest cell cycle progression in G1 and G2
To investigate further the inhibition of DNA synthesis and cell proliferation by wild-type and mutant p21 proteins, we examined cell cycle distribution by¯ow cytometry after staining for DNA content. Cells cultured in the presence or absence of tetracycline for 96 h were double-stained with propidium iodide and anti-HA monoclonal antibody as described in Materials and methods. In the presence of tetracycline, the cell cycle distribution was similar for all cell lines with about 58%, 19% and 23% of cells in G1, S and G2/M phases respectively (Figure 4 ). In the absence of tetracycline, expression of wild-type p21 resulted in a striking decrease in the number of cells in S-phase and accumulation of cells with either a G1 (67%) or a G2/M (31%) DNA content (Figure 4) . A similar accumulation of cells in G1 and G2/M was still observed after 7 days of culture in the absence of tetracycline (data not shown), indicating that expression of p21 causes a stable G2/M growth arrest rather than a transient G2 delay. We concluded that expression of wild-type p21 in DLD1 colon cancer cells arrests cell cycle progression in both G1 and G2/M. We next investigated the eect of p21 CDK7 mutant on cell cycle progression after culture in the absence of tetracycline for 96 h. We found that, similarly to wild-type p21, expression of this p21 CDK7 mutant causes G1 and G2/M blocks (Figure 4 ). This later result suggests that the ability of p21 to induce G1 and G2/M cell cycle blocks in DLD1 cells is not dependent on its association with CDKs. In contrast, p21-induced G1 and G2/M cell cycle arrest is likely to be dependent on p21 binding to PCNA, since the mutant p21 PCNA7 failed to block cell cycle progression in G1 and G2/M (Figure 4 ). Although progression into S and G2 phases appeared to be slightly delayed in cells expressing this p21 PCNA7 mutant, this eect was transient and a cell cycle pro®le similar to parental DLD1 cells was observed after 7 days of culture in the absence of tetracycline. Thus, expression of p21 in DLD1 colon cancer cells inhibits proliferation and causes cell cycle arrest in G1 and G2/M. This eect is not dependent upon association of p21 with CDKs, but appears to require interaction with PCNA. WT and p21 PCNA7 synthetic peptides based on the sequence of p21 (residues 141 ± 160) were synthesized with a carrier penetratin 16-mer peptide (boxed) (Derossi et al., 1994) . Peptide p21 PCNA7 carries the following three substitutions, Met7 to Ala, Asp9 to Ala and Phe10 to Ala, underlined in peptide p21 PCNA7 sequence. (b) Percentage of DLD1 cells in S-phase was determined after BrdU incorporation in cells treated for 4 or 24 h, with 25 mM p21 WT peptide, 25 mM p21 PCNA7 peptide or control PBS buer. Percentage of inhibition of S-phase as compared to the control were 55% and 4% respectively after 4 h, and 44% and 12% respectively after 24 h. The results shown here are representative of several independant experiments. (c) SPR (BIAcore) analysis of PCNA-binding properties of p21
WT and p21 PCNA7 peptides. Peptides were injected at concentration ranging from 2.5 mM to 10 mM over a sensorchip on which puri®ed PCNA was covalently coupled (Knibiehler et al., 1996) . The superimposed sensorgrams shown here were obtained after injection of 10 mM peptide solutions. Association and dissociation constants were derived from multiple measurements (see Materials and methods To further characterize the biochemical mechanisms involved in the inhibition of cell cycle progression by p21 in DLD1 colon cancer cells, we analysed the interaction of conditionally expressed wild-type and mutant p21 proteins with CDKs, cyclins and PCNA in vivo. Immunoprecipitation of HA-tagged wild-type and mutant p21 proteins with monoclonal anti-HA antibodies was followed by immunoblotting of the precipitates with anti-CDKs, anti-cyclin A or anti-PCNA antibodies (Figure 5a ). Wild-type p21 was found to interact with all potential partners tested including CDC2, CDK2, CDK4, cyclin A and PCNA. In contrast, mutant p21 CDK7 was unable to interact with CDKs or cyclin A and only associated with PCNA, indicating that the cyclin-binding site which is intact in mutant p21 CDK7 is not sucient to promote stable association with cyclin-CDK complexes in vivo. Furthermore, the observation that this p21 CDK7 mutant binds to PCNA in vivo strongly suggests that the growth inhibitory eect of this p21
CDK7 mutant results from its ability to bind PCNA and provides further Lysates from wild-type or mutant p21 expressing DLD1 cells cultured in the presence (+) or absence (7) of tetracycline were immunoprecipitated with anti-HA 12CA5F mAb. Immunoprecipitates were analysed by Western blot using rabbit polyclonal anti-CDC2, anti-CDK2, anti-CDK4, anti-cyclin A antibodies or anti-PCNA PC10 mAb. Wild-type p21 associates with all CDKs and cyclins tested (CDC2, CDK2, CDK4 and cyclin A) as well as with PCNA. p21 CDK7 does not bind to CDKs nor to cyclins, while p21 PCNA7 does not bind to PCNA. (b) Analysis of CDK2-associated histone H1 kinase activity in DLD1 parental cells or DLD1 derivatives expressing p21, p21 CDK7 or p21 PCNA7 proteins. Lysates (1 mg) from cells cultured in the presence (+) or absence (7) of tetracycline were immunoprecipitated with rabbit polyclonal anti-CDK2 antibodies. Immunoprecipitates were analysed for CDK2 kinase activity using histone H1 as substrate. (c) Analysis of CDK2-associated histone H1 kinase activity following immunodepletion of p21-associated CDKs. Lysates from DLD1 parental cells or DLD1 derivatives expressing HA-tagged p21 WT p21 CDK7 or p21 PCNA7 protein were immunodepleted of p21-associated CDKs by three sequential immunoprecipitations with mouse anti-HA 12CA5F mAb and rabbit polyclonal C-19 antibodies. Residual CDK2 activity was detected as described in b p21 binding to PCNA causes G1 and G2 growth arrest C Cayrol et al support to the possibility that PCNA may be the primary target of p21 in DLD1 colon cancer cells. In agreement with this later possibility, the mutant p21 PCNA7 which does not inhibit cell cycle progression, failed to associate with PCNA ( Figure 5a ). Moreover, this mutant p21 PCNA7 was still capable of interacting with CDK2, CDK4, CDC2 and cyclin A, suggesting that binding of p21 to cyclin-CDK complexes is not sucient to cause growth inhibition in DLD1 colon cancer cells. To determine whether the lack of growth inhibitory activity was due to the failure of mutant p21 PCNA7 to inhibit the activity of cyclinCDKs complexes, we analysed CDK2-associated H1 kinase activity in cells cultured in the presence or absence of tetracycline for 96 h. In the absence of tetracycline, induction of p21 PCNA7 expression resulted in a striking decrease of CDK2-associated histone H1 kinase activity (Figure 5b ), indicating that mutant p21 PCNA7 is a functional inhibitor of CDKs in vivo. A similar level of inhibition was observed in cells expressing wild-type p21 but as expected not in cells expressing mutant p21 CDK7 which does not bind to CDKs. Although p21 and p21 PCNA7 caused a signi®cant reduction of CDK2 activity, inhibition was not complete and a signi®cant CDK2-associated histone H1 kinase activity level was still recovered following immunodepletion of p21-associated CDKs by three sequential immunoprecipitations with monoclonal anti-HA and polyclonal anti-p21 antibodies (Figure 5c ). The residual CDK activity observed is probably sucient for cell proliferation, explaining the inability of mutant p21 PCNA7 to cause growth arrest through inhibition of cyclin-CDKs.
Expression of p21 or p21
CDK7 causes redistribution of PCNA to the insoluble form
In an eort to explain how p21 binding to PCNA may be responsible for inhibition of cell cycle progression in DLD1 colon cancer cells, we ®rst investigated whether this eect could be due to a lowered level of PCNA in these cells. As shown in Figure 6 , quantitative immunoblotting experiments revealed that PCNA levels in DLD1 cells and in the three p21 DLD1-derivatives are similar to those observed in other cell lines, such as DU145 or Hela. We found about 4 pg PCNA per cell, a value close to what has previously been reported for hamster epithelial cell line (Luo et al., 1995) . The ability of p21 to block cell cycle progression of DLD1 cells through inhibition of PCNA is therefore not due to the expression of lower levels of PCNA by these cells. We then investigated whether p21 binding to PCNA may modify the solubility properties of PCNA. For the majority of the cell cycle, PCNA is present in the nucleus in a soluble form and can be readily extracted using nonionic detergents such as Triton X-100, whereas during S-phase or in cells undergoing DNA repair, a fraction of the total PCNA becomes tightly associated with the nucleus (Triton insoluble) (Bravo and McDonaldBravo, 1987; Morris and Mathews, 1989; Pagano et al., 1994; Toshi and Bravo, 1988) . Approximately equal levels of soluble and insoluble PCNA were found in an asynchronously growing population of DLD1 parental cells (Figure 7 ). In contrast, PCNA was recruited into the insoluble form in cells expressing wild-type p21 or mutant p21
CDK7
. This eect on PCNA solubility was not observed in cells expressing mutant p21 PCNA7 , which does not bind to PCNA. Therefore, the recruitment of PCNA into the insoluble fraction induced by p21 is independent of the ability of p21 to binds to CDKs but is a function of its PCNAbinding activity.
It has been reported by several authors that p21 associates with the detergent-insoluble form of PCNA (Li et al., 1996; Savio et al., 1996) . Therefore, we investigated the solubility properties of wild-type and proteins causes PCNA to redistribute to the insoluble phase. Asynchronous DLD1 parental cells or DLD1 derivatives expressing HA-tagged p21 WT , p21 CDK7 and p21 PCNA7 proteins were grown in the absence of tetracycline for 96 h. Triton-soluble (S) or Triton-insoluble (I) extracts (15 mg/lane) were prepared as described in Materials and methods, subjected to SDS ± PAGE and immunoblotted with anti-PCNA PC10 or anti-HA 12CA5F mAbs p21 binding to PCNA causes G1 and G2 growth arrest C Cayrol et al mutant p21 proteins and found that both p21 and mutant p21 CDK7 relocates to the insoluble form similarly to PCNA. In contrast, levels of mutant p21 PCNA7 , which does not bind PCNA, were similar in the soluble and insoluble fractions. These results suggest that p21 and mutant p21 CDK7 associate with PCNA in insoluble complexes that may play a role in the G1 and G2/M cell cycle arrest induced by these proteins.
Discussion
p21 is unique among the known CKIs in that it interacts with and inhibits two dierent targets, the cyclin-CDK complexes that control cell cycle transitions and the DNA polymerase processivity factor PCNA that is essential for DNA replication. It is now well established that inhibition of cyclin-CDK complexes by p21 can result in cell cycle arrest at the G1/S transition. In contrast, although p21 binding to PCNA has been shown to block DNA synthesis in vivo (Chen et al., 1996a; Luo et al., 1995) , the consequences of this interaction on cell cycle progression have not yet been determined. Here, we show that expression of wild-type p21 or a mutant impaired in the interaction with CDKs (p21 CDK7 ) in p53-de®cient DLD1 human colon cancer cells inhibits cell cycle progression at the G1/S and G2/M transitions and results in the near absence of cells in S-phase. This eect is not observed with a mutant de®cient for the interaction with PCNA (p21 PCNA7 ) indicating that cell cycle inhibition by p21 in these colon cancer cells is dependent on the interaction between p21 and PCNA, but does not require binding of p21 to cyclin-CDK complexes. It has previously been demonstrated that genetic disruption of p21 in DLD1 or HCT116 colon cancer cells abrogates G1 and G2 cell cycle arrest induced by p53 (Polyak et al., 1996) . Our results con®rm and extend these previous ®ndings by showing that p21-induced G1 and G2 cell cycle arrest results from p21 interacting with and inhibiting PCNA. p21 can therefore inhibit cell cycle progression by two independent mechanisms, inhibition of cyclin-CDK complexes and/or inhibition of PCNA function. p21-induced G1 arrest is most likely to result from p21 binding to G1 cyclin-CDK complexes, while p21-mediated G1 and G2 growth arrest, which has been observed in a few cases (Polyak et al., 1996) , may be due to p21 interaction with PCNA. The eectiveness of these two independent mechanisms in cell-cycle inhibition may be determined by the relative abundance of p21, CDKs and PCNA. In most cells, the p21-CDKs pathway may predominate and mask the p21-PCNA pathway. This may explain why overexpression of p21 most often results in G1 arrest rather than both G1 and G2 arrest. In the DLD1 colon cancer cell line used in our study, expression levels of exogenous p21 may not be sucient to block all kinase activity associated with cyclin-CDK complexes. In agreement with this hypothesis, examination of the in vivo association of p21 proteins with CDKs and PCNA revealed that both wild-type p21 and mutant p21 PCNA7 were able to bind to cyclin-CDK complexes but did not completely inhibit their kinase activity. A pool of CDK2 not associated with p21 was found, that may provide sucient CDK2-associated kinase activity to maintain cell proliferation in cells expressing mutant p21 PCNA7 . Therefore, although the levels of p21 after tetracycline removal are high and quite comparable to what is observed in normal ®broblasts after u.v. irradiation, it is still possible that the overall pool of CDKs may overcome p21 levels. Alternatively, the interaction between p21 and the cyclin-CDK complexes might be prevented by the association of the active kinase complexes with another regulator that would play a`protective' role. This will explain the relative`insensitivity' of CDKs to the p21 inhibitory function in DLD1 colon cancer cells. Such a protective mechanism could also provide an explanation to the observation that many tumor cells are able to tolerate high levels of p21 without any growth impairment (Barboule et al., 1995; Jung et al., 1995) .
The observation that PCNA is the primary target for p21-dependent inhibition of cell proliferation in DLD1 colon carcinoma cells raises major questions concerning the molecular mechanisms involved in PCNA-dependent p21-induced G1 and G2 growth arrest. As an auxiliary factor for DNA polymerases d and e, PCNA plays a key role in DNA replication by forming a sliding clamp that tethers the polymerases to DNA during strand synthesis. It is therefore not surprising that inhibition of PCNA by p21 or a p21-derived PCNAbinding peptide actually results in inhibition of in vivo DNA synthesis. This inhibition of PCNA-dependent DNA synthesis may explain the G1 and G2 arrest observed in cells expressing p21 or mutant p21 CDK7 . Many cells expressing these proteins may fail to initiate DNA replication and thus accumulate with a G1 DNA content. Other cells that start but fail to complete DNA replication may arrest in G2/M because the presence of incompletely replicated DNA results in the activation of a G2/M cell cycle checkpoint. Interestingly, we have recently found that expression of p21 in the ®ssion yeast Schizosaccharomyces pombe blocked cell cycle progression in G2 (Tournier et al., 1996) . This eect resulted exclusively from the association of p21 with PCNA and worked through the activation of a DNA damage checkpoint pathway involving the rad3 + and chk1 + genes. PCNA-dependent cell cycle inhibition by p21 was largely abolished by deletion of the chk1 + gene that monitors radiation damage and was considerably enhanced in cells deleted for the rad3 + gene that monitors both DNA damage and the completion of DNA synthesis. Since rad3 + encodes a member of the ATM (ataxia telangiectasia mutated)-related family, with remarkable similarity to the mammalian ATR (AT and rad-related) kinase, this checkpoint pathway may be conserved in mammals (Elledge et al., 1996; Enoch and Norbury, 1995) . Therefore, it will be important in the future to con®rm that p21 binding to PCNA results in the activation of a G2/M checkpoint pathway and to determine whether ATM and/or ATR kinases play a role in this p21-induced pathway.
Mammalian cells contain two distinct populations of PCNA that are cell cycle regulated, one is soluble and the other is tightly associated with the replication machinery in the nucleus during S-phase and is detergent insoluble (Bravo and McDonald-Bravo, 1987; Morris and Mathews, 1989 ). In addition, a similar subset of PCNA resistant to detergent extraction from the nucleus has p21 binding to PCNA causes G1 and G2 growth arrest C Cayrol et al also been found in non-S-phase cells undergoing DNA repair following u.v.-irradiation (Toshi and Bravo, 1988) . In this study, we found that expression of p21 or p21 CDK7 , which both inhibit cell proliferation, causes redistribution of PCNA to the insoluble form. This eect appears to be speci®c since it was not observed with mutant p21 PCNA7 which does not bind to PCNA. Interestingly, it has similarly been shown in the ®ssion yeast model that p21 expression relocates PCNA to the insoluble fraction, thus mimicking the eects of DNA damage induced by u.v.-illumination or exposure to phleomycin (Tournier and Hyams, personal communication) . This further suggests that similar mechanisms are involved in the growth arrest pathway induced by p21 binding to PCNA in ®ssion yeast and human colon cancer cells. It is therefore conceivable that p21 expression in DLD1 cells, by promoting the relocation of PCNA to the insoluble form, may mimic a DNA damage and activate checkpoint mechanisms that in turn inhibit cell cycle progression. Alternatively, relocation of p21 and PCNA to a detergent-insoluble fraction tightly associated with the nuclei may alter the function of soluble cyclin-CDK-p21-PCNA quaternary complexes that are found during the G1 and G2 phases of the cell cycle (Zhang et al., 1993) . One possible function proposed for the p21-mediated association of PCNA with multiple cyclin/CDK complexes is that PCNA may bring the active kinases close to their substrates and sites of activity during speci®c stages of the cell cycle (LaBaer et al., 1997; Zhang et al., 1993) . Redistribution of PCNA and p21 to the insoluble form in cells expressing wildtype p21 or mutant p21 CDK7 may thus contribute to the observed G1 and G2/M arrest by modifying the assembly, stoechiometry and/or subcellular targeting of the cyclin-CDK-p21-PCNA quaternary complexes involved in G1/S and G2/M cell cycle transitions. Further studies will be required to determine whether these later mechanisms are involved in the p21-induced G1 and G2/ M growth arrest and to fully understand the role of these cyclin-CDK-p21-PCNA quaternary complexes in cell cycle progression, DNA replication and DNA repair.
Materials and methods

Plasmids and constructions
Oligonucleotide directed mutagenesis was performed on pBS-p21 vector (kindly provided by Dr D Beach, Cold Spring Harbor, NY), to obtain p21 CDK7 and p21 PCNA7 mutants. In mutant p21 CDK7 , amino-acids W49, F51 and D52 were changed to R49, S51 and A52 while in mutant p21 PCNA7 , residues M147, D149 and F150 were changed to A147, A149 and A150. Wild-type and mutated p21 cDNAs were digested with EcoRI and BamHI restriction enzymes, and cloned into EcoRI and BamHI sites of pUHD10 vector (a generous gift from Dr H Bujard, University of Heidelberg; Gossen and Bujard, 1992) , to give rise to pUHD10-p21, pUHD10-p21 CDK7 and pUHD10-p21 PCNA7 plasmids. A triple hemagglutinin (HA) tag sequence was then inserted into a unique NotI site, introduced at the Cterminus by site directed mutagenesis using p21-NotI primer (5'-CCTGTGGGCGGATTAGCGGCCGCCGGG-CTTCCTCTTGGA-3'). All constructs were sequenced to verify that the triple HA tag had been correctly inserted and that the desired mutations had been introduced with no additionnal mutations.
Cell lines and culture
DU145 prostate carcinoma and DLD1 colon carcinoma cell lines expressing tTA transactivator were a generous gift from Dr Y Chen, Wayne State University, Detroit. Stable cell lines expressing p21 and the mutant forms of p21, p21 CDK7 and p21 PCNA7 , were generated by cotransfecting DLD1-tTA parental cell line with pUHD10-p21
WT , pUHD10-p21 CDK7 and pUHD10-p21 PCNA7 vectors respectively, together with pREP-hygro plasmid conferring hygromycin resistance. Selective medium containing 50 mg ml hygromycin (Calbiochem), was added 48 h after transfection. Resistant colonies were picked and analysed for p21 expression by Western blotting analysis and immuno¯uorescence staining. Stable cell lines were maintained in Dulbecco's modi®ed Eagle's medium (DMEM, Seromed) supplemented with 10% foetal calf serum (FCS, Eurobio), 4 mM L-Glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin (Seromed), and tetracycline (2 mg/ml; Sigma) in a 5% CO 2 environment. Expression of wild-type or mutated p21 in transfected cells was induced by the same medium without tetracycline for 96 h. DU145, DLD1 and Hela cell lines were maintained in the same media as described above without tetracycline.
Antibodies, immunoprecipitation and Western blot analysis
Rabbit polyclonal antibodies against HA tag (HA-11), were obtained from BAbCO. Mouse monoclonal anti-HA (12CA5F) antibody was kindly provided by P LeÂ opold (Villefranche/Mer, France). Rabbit polyclonal antibodies anti-p21 (C-19) and mouse monoclonal antibody (mAb) against PCNA (PC10) were purchased from Santa-Cruz Biotech. and Pharmingen respectively. Rabbit polyclonal antisera raised against CDC2, CDK2 and cyclin A have been described elsewhere (Baldin et al., 1993) . Monoclonal mouse antibodies (DCS-35) directed against CDK4 were a generous gift from Dr J Lukas (Danish Cancer Society, Copenhagen). Goat anti-mouse or anti-rabbit antibodies conjugated to Horseradish Peroxidase (HRP) (Biorad) were used as secondary antibody in Western blot analysis. For quanti®cation experiments, we used goat anti-mouse or anti-rabbit Alkaline Phosphatase (AP)-linked antibodies of Vistra ECF Western blotting system (Molecular Dynamics and Amersham). For immunoprecipitation experiments, cells (10 7 ) were washed twice in cold PBS and harvested in 2 ml lysis buer (Tris-HCl 50 mM, pH 7.4; NaCl 150 mM; NP40 0.5%; NaF 50 mM; Na 3 VO 4 1 mM, DTT 1 mM; phenylmethylsulfonyl¯uoride (PMSF) 1 mM; leupeptin 25 mg ml; aprotinin 25 mg ml; trypsin inhibitor 10 mg ml). Lysates were incubated 30 min at 48C and clari®ed by centrifugation at 14 000 r.p.m. for 10 min. 1 mg of cellular extract, as determined by the Bio-Rad protein assay (Biorad), was precleared by incubating extracts with protein A sepharose (50% vol/vol; Pharmacia) for 1 h at 48C. Precleared extracts were then incubated with primary antibody overnight at 48C and the immune complexes were collected by incubation (1 h, 48C with rocking) with protein A Sepharose. Immunoprecipitates were washed four times with ice cold lysis buer, eluted in 26SDS sample buer (SDS sample buer 16 : Tris-HCl, 50 mM pH 6.8; SDS 2%, glycerol 10%, 5% b-mercaptoethanol, bromophenol blue) and resolved on 12% SDS-polyacrylamide gel electrophoresis. For subsequent immunoblotting, proteins were electrotransferred to nitrocellulose membrane (Hybond-C extra, Amersham). Membranes were blocked for 30 min in 5% non fat milk, in TBST (Tris 20 mM, pH 7.6; NaCl 150 mM, Tween 0.2%), probed overnight at 48C with primary antibody, washed four times with TBST, probed with AP-or HRP-conjugated secondary antibody for 3 h at room temperature, and washed again four times in TBST. Antigen/antibody reaction was revealed using enhanced chemiluminescence (ECL) or chemi¯uorescence (ECF) p21 binding to PCNA causes G1 and G2 growth arrest C Cayrol et al procedures according to the manufacturers' recommendations (Rennaissance, NEN and Vistra ECF Western blotting system, Amersham respectively). For quanti®cation experiments, antigen/antibody reaction was quanti®ed after ECF on a Storm 840 imager (Molecular Dynamics) using the ImageQuant software.
Release of detergent-insoluble PCNA and p21
Cell extracts were prepared as described (Pagano et al., 1994) . Brie¯y, wild-type or mutant p21 expressing DLD1 cells (5610 6 ) were resuspended in 2 ml lysis buer (TrisHCl 50 mM pH 7.4; NaCl 250 mM, 0.1% Triton6100; 1 mM EDTA; 50 mM NaF; 1 mM DTT; 0.1 mM Na 3 VO 4 ; 0.1 mM PMSF, 1 mg ml leupeptin, 10 mg ml trypsin inhibitor, 1 mg ml aprotinin) and incubated for 30 min at 48C. The Triton-soluble fraction (supernatant) was recovered by centrifugation at 14 000 r.p.m. for 5 min, at 48C. The pellet was resuspended in 2 ml lysis buer containing 1% SDS and samples were incubated at 48C for 30 min. The Triton-insoluble fraction (supernatant) was recovered by centrifugation at 14 000 r.p.m. for 5 min, at 48C. Immunoblotting was performed as described above.
Histone H1 kinase assay
For Histone H1 kinase assay, immunoprecipitations were performed as described above. Immunoprecipitates were washed twice with kinase buer (Tris-HCl 50 mM pH7.5, MgCl 2 10 mM, DTT 1 mM). Beads were resuspended in 20 ml kinase buer containing 1 mg histone H1 (Boehringer Mannheim), 5 mCi of [g 32 P]ATP (NEN), 50 mM cold ATP. Kinase reactions were carried out for 15 min at 308C, and stopped by addition of 5 ml of 56SDS sample buer. The samples were heated (708C, 10 min) and subjected to SDS ± PAGE; gels were ®xed, dried and histone H1 kinase activity was visualized and quantitated as described above. The amount of CDKs precipitated in each experiment was determined by Western blot analysis.
Immuno¯uorescence microscopy
Cells were seeded on glass coverslips at a density of 10 4 cells/cm 2 and allowed to adhere 2 days. Cells were ®xed in formaldehyde (4% w/v in PBS, 15 min), and incubated in 50 mM NH4Cl for 10 min, at room temperature. Cells were permeabilised by incubation in 0.1% Triton 6100 for 13 min and blocked with 20% heat-inactivated calf serum for 15 min. Cells were then incubated with anti-HA mAb for 1 h, followed by incubation with a Texas ± Red conjugated goat anti-mouse secondary antibody (Amersham). Slides were dried, mounted in Mowiol containing 0.1 mg ml 4'-6 diamino-2-phenylindole (DAPI) and visualized under a¯uorescence microscope (Zeiss).
Cell cycle analysis
The eects of wild-type and mutant p21 proteins on cell cycle distribution were analysed by FACS. In order to circumvent p21 expression heterogeneity within a clone, DNA content determination was performed on the p21 positive cells, detected by anti-HA mAb. Induced cells (5610 6 ) were trypsinized, ®xed in formaldehyde for 15 min, and permeabilized with Triton 6100 (0.1% in PBS) for 13 min. Cells were then stained with primary anti-HA mAb for 1 h on ice, followed by two washes with PBS. Cells were then incubated with secondary FITC-conjugated goat anti-mouse antibody (Amersham) for 45 min on ice followed by two more washes with PBS. Cells were then stained with propidium iodide, by incubation for 30 min at 378C in 38 mM sodium citrate buer containing propidium iodide (69 mM) and RNase I (0.1 mg/ml). Cell cycle analysis was carried out on a FACScan (Beckton Dickinson).
Analysis of DNA synthesis by BrdU labeling DNA synthesis was analysed by measuring BrdU incorporation in cells expressing wild-type or mutant p21. Parental DLD1 cell line and DLD1 derivatives expressing wild-type or mutant p21 proteins were labeled for 30 min with 50 mM BrdU (Sigma), ®xed, permeabilized and stained with polyclonal anti-HA antibodies (BAbCO) and Texas-Red-linked anti-rabbit antibodies (Amersham) to detect p21 positive cells. Cells were ®xed again with formaldehyde, denatured in 2 M HCl for 1 h at 378C and incubated with 0.1 M sodium tetraborate, pH 8.5 for 5 min. Cells were then incubated with a mouse mAb against BrdU (Bu20a, DAKO) and a FITC-conjugated anti-mouse antibody (Amersham), washed in PBS and mounted on glass slides with Mowiol containing nuclei staining dye DAPI. At least 200 cells were counted for each condition and each single experiment was repeated at least twice.
PCNA binding and DNA synthesis inhibition by p21-derived peptides
To con®rm that p21 binding to PCNA was responsible for the observed growth arrest, we used chimeric synthetic peptides, containing both C-terminal p21 sequence (residues 141 ± 160) and a 16 amino acid sequence (RQIKIWFFQNRRMKWKK) derived from the homeodomain of the Antennapedia protein which has been shown to act as a carrier (Derossi et al., 1994) . As a negative control, the same peptide containing M/A, D/A and F/A mutations at position 7, 9 and 10 was used (see Figure 3a) . The purity of the peptides was estimated using mass spectrometry. The peptides were dissolved in PBS, at a concentration of 250 mM. We con®rmed that p21 peptide was able to bind to PCNA and that mutated p21 peptide abrogate PCNA binding using surface Plasmon Resonance (SPR) technology. For DNA synthesis analysis, peptides were added to the culture media at a ®nal concentration of 25 mM, for 4 or 24 h, as previously described . Treated DLD1 cells were then incubated for 1 h with 50 mM BrdU. Cells were ®xed with formaldehyde, denatured in 2 M HCl for 1 h at 378C and stained with a mouse anti-BrdU mAb (Bu20a, DAKO) followed by a FITC-conjugated anti-mouse antibody. After extensive washing, cells were mounted on slides with Mowiol containing DAPI, visualized and counted with a Zeiss microscope. A minimun of 200 cells were counted for each condition and experiments were repeated at least twice with similar results.
SPR analysis
The upgraded BIAcore system, CM5 research grade sensor chips, coupling agents and HBS buer were purchased from BIAcore (Uppsala, Sweden).
Puri®ed PCNA (a gift of Dr U HuÈ bscher, Zurich) was covalently coupled to the dextran of sensor chip CM5 research grade. The carboxymethylated dextran was ®rst activated during 8 min (10 ml min 71¯o w rate) with 0.1 M Nhydroxysuccinimide (NHS) and 0.4 M N-ethyl-N'-(dimethylaminopropyl)carbodiimide (EDC) in water. The ligand was then injected through the reactive surface (180 ml 2 mM of PCNA) in 10 mM NH4 buer (pH 4.5) with a continuous ow of HBS (10 ml/min). The residual NHS-esters on the sensorchip surface were then deactivated during 8 min with ethanolamine 1 M, pH 8.5 in water. Final regeneration of the matrix was performed with 10 mM HCl and then 10 mM NaOH.
p21 binding to PCNA causes G1 and G2 growth arrest C Cayrol et al Peptides were diluted in 20 mM Tris pH 8.4. A 25 ml sample was injected over the PCNA coupled surface during 2.5 min at a 10 ml min¯ow rate. Multiple injections at various concentrations were performed. For each concentration a control injection was performed on an activated ± desactivated¯owcell. The sensorgrams were recorded and, after substraction of the control, the data were ®tted to a single site binding model by non-linear least squares curve ®tting using the BIAevaluation 2.1 software. The apparent dissociation rate constant k o was calculated by iterative ®tting to ®rst order model. For the association phase, we calculated k s (k s is the slope of the plot of instant rate dR/dt vs R), at various concentration (C) of analyte and the association rate constant k on was calculated by the linear curve ®tting of a plot of k s versus C on model 1 (A+B=AB).
